2. Table 2. Bookman 2009: Treatment plan.
| Variable | Treatment Arm | ||||
| I (Reference) | II | III | IV | V | |
| Carboplatin, C1-4 | AUC6 D1 | AUC5 D2 | AUC5 D1 | AUC5 D3 | AUC6 D8 |
| Paclitaxel, C1-4 | 175mg/m2 D1 (3 hours) | 175mg/m2 D1 (3 hours) | 175mg/m2 D1 (3 hours) | ‐ | ‐ |
| Gemcitabine, C1‐8 | ‐ | 800mg/m2 D1, 8(30 minutes) | ‐ | ‐ | ‐ |
| Gemcitabine, C1‐4 | ‐ | ‐ | ‐ | ‐ | 1000mg/m2/d D1,8 |
| PLD, C1, 3, 5, 7 | ‐ | ‐ | 30mg/m2D1 | ‐ | ‐ |
| Topotecan, C1‐4 | ‐ | ‐ | ‐ | 1.25mg/m2/dD1,2,3 | ‐ |
| Carboplatin, C5‐8 | AUC6 D1 | AUC5 D1 | AUC5 D1 | AUC6 D1 | AUC6 D1 |
| Paclitaxel, C5‐8 | 175mg/m2 D1 (3 hours) | 175mg/m2 D1 (3 hours) | 175mg/m2 D1 (3 hours) | 175mg/m2 D1 (3 hours) | 175mg/m2 D1 (3 hours) |
Each arm included eight cycles of triplet or sequential‐doublet chemotherapy, which provided a minimum of four cycles that incorporated experimental treatments while maintaining at least four cycles with carboplatin and paclitaxel.